Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
tremelimumab
Tremelimumab is a selective, human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T-cell activity primarily expressed on the surface of T lymphocytes. By binding to CTLA-4, tremelimumab blocks interaction of the receptor with its ligands CD80 and CD86, thereby enhancing T-cell activation and proliferation, resulting in increased T-cell diversity and enhanced antitumour immune activity.
| Time to reach steady state |
12 weeks (in patients with solid tumours who received 1 mg/kg, 3 mg/kg, and 10 mg/kg doses once every 4 weeks x 4 doses) |
| Volume of distribution |
central > peripheral |
| Cross blood brain barrier? |
Unknown |
| PPB |
Unknown; albumin levels had no clinically significant effect on PK |
Not metabolized via hepatic pathways due to its large molecular weight; eliminated through protein catabolism via reticuloendothelial system or target mediated disposition.
| Half-life |
16.9 days (after single 300mg dose) 18.2 days (at steady state) |
- Hepatocellular carcinoma (HCC)
Refer to the product monograph for a full list and details of approved indications
Emetogenic Potential:
The following table lists adverse effects that occurred in ≥ 2% of patients receiving a combination of tremelimumab and durvalumab in a phase III, randomized, open-label study in unresectable HCC. It also includes severe, life-threatening and post-marketing adverse effects from other sources.
| ORGAN SITE | SIDE EFFECT* (%) | ONSET** | |||
|---|---|---|---|---|---|
| Cardiovascular | Myocarditis (<1%) | D L | |||
| Dermatological | Rash, pruritus (30%) (including dermatitis, 2% severe) | D L | |||
| Stevens-Johnson syndrome (<1%) | E | ||||
| Gastrointestinal | Abdominal pain (19%) (2% severe) | E | |||
| Colitis (7%) (4% severe) | E | ||||
| Diarrhea (27%) (4% severe) | E | ||||
| GI perforation (<1%) | E | ||||
| General | Edema (9%) (peripheral) | E | |||
| Fever (13%) | I E | ||||
| Hepatobiliary | ↑ Amylase / lipase (9%) (6% severe) | E | |||
| ↑ LFTs (15%) (6% severe, including hepatitis) | D | ||||
| Pancreatitis (2%) | E | ||||
| Hypersensitivity | Infusion related reaction (2%) | I | |||
| Infection | Infection (8%) | E | |||
| Metabolic / Endocrine | Adrenal insufficiency (2%) | D | |||
| Hyperglycemia (<1%) | D | ||||
| Hyperthyroidism (10%) | D | ||||
| Hypophysitis (1%) | D | ||||
| Hypothyroidism (13%) | D | ||||
| Thyroiditis (2%) | D | ||||
| Musculoskeletal | Musculoskeletal pain (3%) (myalgia, immune-mediated arthritis - rare) | E | |||
| Nervous System | Guillain-Barre syndrome (<1%) | E | |||
| Other (<1%) Myasthenia gravis, myositis | E | ||||
| Ophthalmic | Eye disorders (retinal detachment, uveitis) (rare) | E | |||
| Renal | Creatinine increased (4%) (may be severe - nephritis rare) | D | |||
| Respiratory | Cough (9%) | E | |||
| Pneumonitis (3%) | E | ||||
* "Incidence" may refer to an absolute value or the higher value from a reported range.
"Rare"
may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies,
isolated data or anecdotal
reports.
** I = immediate (onset in hours to days)
E = early (days to weeks)
D = delayed (weeks to months)
L = late (months to years)
The most common side effects for tremelimumab include rash, pruritus, diarrhea, abdominal pain, ↑ LFTs, fever and hypothyroidism.
Refer to CCO's Immune Checkpoint Inhibitor Toxicity Management Guideline for detailed descriptions of Immune-related toxicities and their management.
Presentation of immune-mediated reactions may be different compared to other anti-cancer agents and early diagnosis and appropriate management is critical.
Immune-related reactions including rash, pneumonitis, colitis, hepatitis, pancreatitis, nephritis, endocrinopathies and neuropathies were reported and may be severe or fatal. Onset may vary from days to many months and may occur after treatment has ended.
Other immune-mediated adverse reactions have been reported in patients that received tremelimumab in combination with durvalumab, including encephalitis and immune thrombocytopenia.
Immune-related reactions occurred more often in patients who received tremelimumab in combination with durvalumab compared to durvalumab alone.
Refer to protocol by which the patient is being treated.
Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the hepatitis B virus screening and management guideline.
Avoid the use of corticosteroids or immunosuppressants before starting treatment*.
* doses of ≤ 10 mg/day of prednisone or its equivalent were permitted in the HIMALAYA study
Combination therapy for HCC:
Intravenous: 300* mg as a single dose on Day 1 of Cycle 1
*For patients with body weight ≤ 30 kg use weight-based dosing: 4mg/kg
Refer to the DURV+TREM regimen monograph for durvalumab dosing.
- Healthcare professionals should also consult the most recent tremelimumab product monograph for additional information.
- Dose reductions are not recommended for tremelimumab. Doses may be delayed or discontinued based on toxicity.
Summary of Principles of Management or immune-related adverse effects (iRAEs)
-
Immune-related adverse effects (irAEs) are different in their presentation, onset and duration compared to conventional chemotherapy. Patient and provider education is essential.
-
Initial irAE presentation can occur months after completion of treatment and affect multiple organs.
-
Dose escalation or reduction is not recommended.
-
If no other cause can be identified (such as infection), any new symptom should be considered immune-related and prompt treatment initiated.
-
Organ-specific system-based toxicity management is recommended.
-
Refer to CCO's Immune Checkpoint Inhibitor Toxicity Management Guideline for detailed descriptions of Immune-related toxicities and their management.
Non-immune-related toxicity:
| Severity | Action |
| Grade 2 or 3 | Hold until ≤ Grade 1 or baseline |
| Grade 4* | Discontinue |
*Decision to discontinue for lab abnormalities should be based on signs/ symptoms and clinical judgement.
Management of Infusion-related reactions:
Also refer to the CCO guideline for detailed description of Management of Cancer Medication-Related Infusion Reactions.
| Grade | Management | Re-challenge |
| 1 or 2 |
|
|
| 3 or 4 |
|
|
| Bilirubin | AST | Tremelimumab Dose | |
| ≤ ULN | AND | > ULN |
No dose adjustment required |
| >1.0 to 1.5 × ULN | AND | any | |
| >1.5 to 3 x ULN | AND | any | |
| >3.0 x ULN | AND | any | Not data available |
| Creatinine Clearance (mL/min) | Tremelimumab Dose |
| ≥ 30 | No dose adjustment required |
| < 30 | Not data available |
No dose adjustment is required for patients ≥ 65 years of age. No overall differences in efficacy were observed between patients ≥ 65 years of age and younger patients. However, rates of adverse events were higher in patients ≥65 compared to those < 65 years old in clinical trials.
No dose adjustment is recommended based on gender.
No dose adjustment is recommended based on race.
Safety and effectiveness in patients younger than 18 years of age have not been established.
- Dilute in a 0.9% sodium chloride or D5W IV bag to a final concentration between 0.1 mg/mL and 10 mg/mL. Mix by gentle inversion.
- Compatible with polyvinylchloride and polyolefin IV bags.
- Infuse IV over 60 minutes using a sterile, low-protein binding 0.2 or 0.22 micron in-line filter.
- Give tremelimumab prior to durvalumab when administered on the same day.
- Monitor patient for 60 minutes after tremelimumab infusion.
- Do not mix with other drugs or co-administer other drugs through the same infusion line. Flush the line after each dose.
-
Store unopened vials under refrigeration (2 to 8oC) and protect from light. Do not freeze or shake.
- Patients who have a hypersensitivity to this drug or any of its components.
- Tremelimumab (in combination with durvalumab) may cause serious immune-mediated reactions affecting multiple organ systems including GI, hepatic, cardiac, respiratory, endocrine and others. Use with caution and monitor closely in patients with pre-existing autoimmune disease and conditions such as colitis, hepatic impairment, respiratory or endocrine disorders, such as hypo or hyperthyroidism or diabetes mellitus.
- Consider the benefit/risk in patients with autoimmune or inflammatory disorders, prior GI bleeds (within 12 months), history of organ transplant, co-infection with hepatitis B and C, hepatic encephalopathy, main portal vein thrombosis, or Child-Pugh Class B or Class C; these patients were excluded from clinical trials.
Other Drug Properties:
-
Carcinogenicity:
Unknown
-
Crosses placental barrier:
Yes
Human IgG2 is known to cross the placental barrier
-
Fetotoxicity:
Documented in animals
In animal studies, CTLA-4 blockade is associated with an increased risk of immune-mediated rejection of the developing fetus and fetal death.
Tremelimumab is not recommended for use in pregnancy. Adequate contraception should be used by patients and their partners during treatment, and for at least 3 months after the last dose.
-
Excretion into breast milk:
Unknown
Breastfeeding is not recommended during treatment and for at least 3 months after the last dose.
-
Fertility effects:
Unknown
Tremelimumab is not not expected to have pharmacokinetic drug-drug interactions as it is not metabolized by CYP450 enzymes or other hepatic pathways. No formal drug interaction studies have been conducted.
Use of systemic corticosteroids or immunosuppressants should be avoided prior to starting tremelimumab because of potential interference with efficacy. They can be used to treat immune-mediated reactions after starting the drug.
Acetaminophen may affect the response to immune checkpoint inhibitors. Further clinical studies are needed to determine the exact mechanism and the appropriate clinical management (Bessede et al, 2022).
Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.
Refer to the hepatitis B virus screening and management guideline for monitoring during and after treatment.
| Monitor Type | Monitor Frequency |
|---|---|
Liver function tests (AST, ALT, bilirubin) |
Baseline and as clinically indicated |
Renal function tests |
Baseline and as clinically indicated |
CBC |
Baseline and as clinically indicated |
Thyroid function tests |
Baseline and as clinically indicated |
Blood glucose |
Baseline and as clinically indicated |
Clinical toxicity assessment for infection, fatigue, infusion-related and immune-related reactions, including GI, skin, endocrine, musculoskeletal, respiratory, ocular, cardiac, neurologic toxicity or pancreatitis. |
At each visit |
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
New Drug Funding Program (NDFP Website )
- Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 2022;1(8):1-12.
Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 2022; Suppl:1-35.
Antiemesis. Version 1.2024. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023 December 13
Bessede A, Marabelle A, Guegan JP, et al. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol 2022;33(9):909-15.
CADTH Reimbursement Review. Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi). Canadian Journal of Health Technologies 2024;4(1):1-186
Lim K, Abegesah A, Fan C, et al. Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma. J Clin Pharmacol. 2023 Nov;63(11):1221-1231.
Product Monograph: Tremelimumab (Imjudo). AstraZeneca Canada Inc. 2024 January 26
Product Information: Tremelimumab (Imjudo). AstraZeneca. European Medicines Agency. 2024 March 13
Clinical Study Protocol: D419CC00002. A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA). Astra Zeneca. 2017 August 9
Prescribing Information: Tremelimumab-actl (Imjudo). AstraZeneca Pharmaceuticals LP (U.S.). 2023 June
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126.
Tremelimumab: Drug information. Lexi-Comp Inc., 2024. Accessed February 26, 2024.
April 2024 New Drug Monograph
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.